Quantum BioPharma (NASDAQ: QNTM) has drawn national media attention after Men’s Fitness article by Lakshan Weeraratne examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The coverage matters for the Long Beach and surrounding business community because it puts a small, development-stage biopharmaceutical company and its consumer-facing licensing strategy in front of a mainstream fitness audience, potentially shaping how investors and consumers view the emerging alcohol recovery category.
The Men’s Fitness article highlighted findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo.
The article also emphasized the study’s limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive.
For the industry, the coverage illustrates the scrutiny facing consumer health products that emerge from pharmaceutical research. Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., which is led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026. The agreement also includes royalty payments of 7% of sales from Unbuzzd until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Separately, Quantum describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is focused on research and development of its lead compound, Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
Readers and investors can review the full terms of use and disclaimers applicable to content provided by IBN at https://IBN.ai/Disclaimer. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The original release was distributed through www.newmediawire.com.
The implications extend beyond a single product. For Quantum, favorable mainstream coverage could support the commercial trajectory of Unbuzzd and the royalty stream tied to it, while the study’s acknowledged limitations may invite closer scrutiny from regulators, investors and consumers. For the broader alcohol recovery market, the article underscores that early-stage findings, however promising, require independent validation before they can be treated as established evidence. Companies operating in this space will likely face pressure to demonstrate transparency about sponsorship and to pursue larger trials that can withstand scientific and public review.
